Cargando…

Dysregulation of immunity in COVID-19 and SLE

The immune response plays a crucial role in preventing diseases, such as infections. There are two types of immune responses, specific and innate immunity, each of which consists of two components: cellular immunity and humoral immunity. Dysfunction in any immune system component increases the risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Hejazian, Seyyed Sina, Hejazian, Seyyedeh Mina, Farnood, Farahnoosh, Abedi Azar, Sima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417079/
https://www.ncbi.nlm.nih.gov/pubmed/36028612
http://dx.doi.org/10.1007/s10787-022-01047-2
_version_ 1784776625959731200
author Hejazian, Seyyed Sina
Hejazian, Seyyedeh Mina
Farnood, Farahnoosh
Abedi Azar, Sima
author_facet Hejazian, Seyyed Sina
Hejazian, Seyyedeh Mina
Farnood, Farahnoosh
Abedi Azar, Sima
author_sort Hejazian, Seyyed Sina
collection PubMed
description The immune response plays a crucial role in preventing diseases, such as infections. There are two types of immune responses, specific and innate immunity, each of which consists of two components: cellular immunity and humoral immunity. Dysfunction in any immune system component increases the risk of developing certain diseases. Systemic lupus erythematosus (SLE), an autoimmune disease in the human body, develops an immune response against its own components. In these patients, due to underlying immune system disorders and receipt of immunosuppressive drugs, the susceptibility to infections is higher than in the general population and is the single largest cause of mortality in this group. COVID-19 infection, which first appeared in late 2019, has caused several concerns in patients with SLE. However, there is no strong proof of additional risk of developing COVID-19 in patients with SLE, and in some cases, studies have shown less severity of the disease in these individuals. This review paper discusses the immune disorders in SLE and COVID-19.
format Online
Article
Text
id pubmed-9417079
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-94170792022-08-30 Dysregulation of immunity in COVID-19 and SLE Hejazian, Seyyed Sina Hejazian, Seyyedeh Mina Farnood, Farahnoosh Abedi Azar, Sima Inflammopharmacology Review The immune response plays a crucial role in preventing diseases, such as infections. There are two types of immune responses, specific and innate immunity, each of which consists of two components: cellular immunity and humoral immunity. Dysfunction in any immune system component increases the risk of developing certain diseases. Systemic lupus erythematosus (SLE), an autoimmune disease in the human body, develops an immune response against its own components. In these patients, due to underlying immune system disorders and receipt of immunosuppressive drugs, the susceptibility to infections is higher than in the general population and is the single largest cause of mortality in this group. COVID-19 infection, which first appeared in late 2019, has caused several concerns in patients with SLE. However, there is no strong proof of additional risk of developing COVID-19 in patients with SLE, and in some cases, studies have shown less severity of the disease in these individuals. This review paper discusses the immune disorders in SLE and COVID-19. Springer International Publishing 2022-08-26 2022 /pmc/articles/PMC9417079/ /pubmed/36028612 http://dx.doi.org/10.1007/s10787-022-01047-2 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Hejazian, Seyyed Sina
Hejazian, Seyyedeh Mina
Farnood, Farahnoosh
Abedi Azar, Sima
Dysregulation of immunity in COVID-19 and SLE
title Dysregulation of immunity in COVID-19 and SLE
title_full Dysregulation of immunity in COVID-19 and SLE
title_fullStr Dysregulation of immunity in COVID-19 and SLE
title_full_unstemmed Dysregulation of immunity in COVID-19 and SLE
title_short Dysregulation of immunity in COVID-19 and SLE
title_sort dysregulation of immunity in covid-19 and sle
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417079/
https://www.ncbi.nlm.nih.gov/pubmed/36028612
http://dx.doi.org/10.1007/s10787-022-01047-2
work_keys_str_mv AT hejazianseyyedsina dysregulationofimmunityincovid19andsle
AT hejazianseyyedehmina dysregulationofimmunityincovid19andsle
AT farnoodfarahnoosh dysregulationofimmunityincovid19andsle
AT abediazarsima dysregulationofimmunityincovid19andsle